A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy (CN), metastasectomy (MS) or post-treatment biopsy (Bx).
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jianjun Gao, Jose A. Karam, Nizar M. Tannir, Rebecca Slack, Kamran Ahrar, Priya Rao, Chaan S. Ng, Eric Jonasch, Matthew T. Campbell, Surena F. Matin, Amado J. Zurita, Jennifer Wang, Jorge M Blando, Hao Zhao, Luis M Vence, Sreyashi Basu, Hong Chen, James Patrick Allison, Christopher G. Wood, Padmanee Sharma
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2889603917